Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
PHILADELPHIA, Feb. 08, 2023 - Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:40 a.m. E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PHILADELPHIA, Feb. 08, 2023 - Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:40 a.m. E.T. The event will be held virtually.
Investors can access the live audio webcast through the company’s investors section on their website. Amicus Therapeutics focuses on developing high-quality medicines for rare diseases, emphasizing patient care and innovative solutions. The company is committed to advancing its pipeline, aiming for first- or best-in-class treatments for patients.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was -0.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference, being held virtually, on Wednesday, February 15, 2023 at 10:40 a.m. E.T.
A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.